Joe Jimenez

Joe Jimenez, former Novartis CEO and now co-founder of Aditum Bio focused on translational medicine. He traces his path from consumer brands to pharma leadership. He outlines Aditum’s clinic-directed, shared-services model for IND-to-Phase II programs. He explains the firm’s three investment criteria and why they favor predictable biology over early preclinical oncology.